Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer

Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer

Background Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life‐threatening adverse event. The purpose of this study was to evaluate whether the development of immune‐related adverse events (irAEs), especially ILD, was associated with treatment efficac...

Full description

Bibliographic Details
Main Authors: Teppei Sugano, Masahiro Seike, Yoshinobu Saito, Takeru Kashiwada, Yasuhiro Terasaki, Natsuki Takano, Kakeru Hisakane, Satoshi Takahashi, Toru Tanaka, Susumu Takeuchi, Akihiko Miyanaga, Yuji Minegishi, Rintaro Noro, Kaoru Kubota, Akihiko Gemma
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Thoracic Cancer
Subjects:
Immune check inhibitor
immune‐related adverse events
interstitial lung disease
prognosis
Online Access:https://doi.org/10.1111/1759-7714.13364

Similar Items

Similar Items